Xolair omalizumab regulatory update

The U.K.'s NICE issued guidance recommending against the use of Xolair omalizumab from Novartis to treat severe persistent asthma in children aged 6 to 11 years. The guidance is in line with an August final appraisal determination (FAD) (see BioCentury, Aug. 16). The recombinant humanized mAb against IgE is approved in the EU as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma in patients 6 and older. ...